Prabhudas Lilladher's research report on Ipca Laboratories
We upgrade Ipca Labs (IPCA) from Accumulate to BUY given 1) recovery in API segment 2) higher margins ex Unichem 3) steady growth in domestic formulation and 4) attractive valuations. Ipca reported strong EBITDA of Rs5.6bn (up 23% YoY) which was 6% above our estimates aided by Unichem and higher API sales. Q2 EBITDA for Unichem saw recovery QoQ. Export API business witnessed recovery in H1FY26 with 36% YoY growth. Domestic formulation business, which now contributes 40% of revenues and ~55% of EBITDA, continued to outperform and grow at healthy levels. At CMP, the stock is trading at 14.5x EV/EBITDA and 24x PE on Sept 2027E adjusted for Unichem stake.
Outlook
We upgrade stock to Buy from ACCUMULATE with revised TP of Rs1,600/share; valuing at 18x EV/EBITDA on Sept 2027E.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
